Vivo Capital, LLC reported 44 positions worth $1.06B for the quarter ended Jun 30, 2026, down 2.2% on the prior quarter. It opened 7 new positions, added to 6, trimmed 8 and exited 4. Its largest holding is Trevi Therapeutics, Inc. at 8.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TENX Tenax Therapeutics, Inc. | +2.29M | +1,100.0% | $33.34M | 3.43% |
| AVBP ArriVent BioPharma, Inc. | +796.2K | +89.9% | $27.66M | 5.5% |
| ABVX Abivax S.A. | +175.4K | +73.2% | $23.37M | 5.21% |
| ACHV Achieve Life Sciences, Inc. | +2.75M | – | $17.96M | 1.69% |
| EDIT Editas Medicine, Inc. | +3.56M | – | $11.52M | 1.08% |
| ODTX Odyssey Therapeutics, Inc. | +575.0K | – | $10.76M | 1.01% |
| AURA Aura Biosciences, Inc. | +1.17M | – | $8.28M | 0.78% |
| MLTX MoonLake Immunotherapeutics | +400.0K | +40.0% | $7.79M | 2.57% |
| AVTX Avalo Therapeutics, Inc. | +275.0K | – | $5.08M | 0.479% |
| ANRO Alto Neuroscience, Inc. | +173.3K | +16.7% | $4.57M | 3% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ERAS Erasca, Inc. | -8.02M | -66.0% | $147.00M | 7.12% |
| TNGX Tango Therapeutics, Inc. | -775.0K | -36.0% | $24.23M | 4.06% |
| PRAX Praxis Precision Medicines, Inc. | -67.8K | -20.0% | $22.69M | 8.55% |
| MANE Veradermics, Inc | -300.0K | -100.0% | $18.95M | Exited |
| COGT Cogent Biosciences, Inc. | -422.3K | -100.0% | $16.25M | Exited |
| SABS SAB Biotherapeutics, Inc. | -4.12M | -36.1% | $16.07M | 2.68% |
| DBVT DBV Technologies S.A. | -822.8K | -30.8% | $13.49M | 2.85% |
| UNCY Unicycive Therapeutics, Inc. | -1.24M | -69.3% | $5.82M | 0.243% |
| CMPX Compass Therapeutics, Inc. | -1.79M | -18.7% | $3.92M | 1.6% |
| VRDN Viridian Therapeutics, Inc.\DE | -166.3K | -100.0% | $3.25M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ACHV Achieve Life Sciences, Inc. | +2.75M | $17.96M | 1.69% |
| EDIT Editas Medicine, Inc. | +3.56M | $11.52M | 1.08% |
| ODTX Odyssey Therapeutics, Inc. | +575.0K | $10.76M | 1.01% |
| AURA Aura Biosciences, Inc. | +1.17M | $8.28M | 0.78% |
| AVTX Avalo Therapeutics, Inc. | +275.0K | $5.08M | 0.479% |
| VALN Valneva SE | +763.2K | $3.99M | 0.376% |
| INM InMed Pharmaceuticals Inc. | +79.8K | $1.24M | 0.117% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRVI Trevi Therapeutics, Inc. | Healthcare | 5.09M | $95.02M | 8.95% | 0 | 0.0% | Unchanged | 3.25% |
| 2 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 271.1K | $90.77M | 8.55% | -67.8K | -20.0% | Reduced | 0.93% |
| 3 | ERAS Erasca, Inc. | Healthcare | 4.13M | $75.61M | 7.12% | -8.02M | -66.0% | Reduced | 1.32% |
| 4 | AVBP ArriVent BioPharma, Inc. | Healthcare | 1.68M | $58.44M | 5.5% | +796.2K | +89.9% | Added | 3.48% |
| 5 | ABVX Abivax S.A. | Healthcare | 414.9K | $55.29M | 5.21% | +175.4K | +73.2% | Added | 0.6% |
| 6 | TNGX Tango Therapeutics, Inc. | Healthcare | 1.38M | $43.13M | 4.06% | -775.0K | -36.0% | Reduced | 0.82% |
| 7 | CRVS Corvus Pharmaceuticals, Inc. | Healthcare | 2.81M | $41.92M | 3.95% | 0 | 0.0% | Unchanged | 3.04% |
| 8 | DRUG Bright Minds Biosciences Inc. | Healthcare | 557.2K | $39.11M | 3.68% | 0 | 0.0% | Unchanged | 8.1% |
| 9 | SVA Sinovac Biotech Ltd | Healthcare | 5.90M | $38.19M | 3.6% | 0 | 0.0% | Unchanged | 8.21% |
| 10 | TENX Tenax Therapeutics, Inc. | Healthcare | 2.50M | $36.38M | 3.43% | +2.29M | +1,100.0% | Added | 4.91% |
| 11 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 6.69M | $35.41M | 3.34% | +28.0K | +0.4% | Added | 4.69% |
| 12 | DYN Dyne Therapeutics, Inc. | Healthcare | 1.56M | $34.59M | 3.26% | 0 | 0.0% | Unchanged | 0.94% |
| 13 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 354.0K | $34.51M | 3.25% | 0 | 0.0% | Unchanged | 0.63% |
| 14 | ANRO Alto Neuroscience, Inc. | Healthcare | 1.21M | $31.90M | 3% | +173.3K | +16.7% | Added | 2.82% |
| 15 | DBVT DBV Technologies S.A. | Healthcare | 1.84M | $30.25M | 2.85% | -822.8K | -30.8% | Reduced | 2.13% |
Tip. Select a row to see that position’s full history at Vivo Capital.
As of its Q2 2026 13F filing, Vivo Capital, LLC’s five largest positions were Trevi Therapeutics, Inc. (TRVI) at 8.9%, Praxis Precision Medicines, Inc. (PRAX) at 8.5%, Erasca, Inc. (ERAS) at 7.1%, ArriVent BioPharma, Inc. (AVBP) at 5.5%, Abivax S.A. (ABVX) at 5.2% of the reported portfolio.
Vivo Capital, LLC reported a 13F portfolio worth $1.06B across 44 positions for Q2 2026. That is down 2.2% from the previous quarter.
Its largest purchases by value were Tenax Therapeutics, Inc. ($33.34M), ArriVent BioPharma, Inc. ($27.66M), Abivax S.A. ($23.37M). It opened 7 new positions.
Its largest sales by value were Erasca, Inc. ($147.00M), Tango Therapeutics, Inc. ($24.23M), Praxis Precision Medicines, Inc. ($22.69M). It exited 4 positions entirely.
From the Form 13F-HR reports Vivo Capital, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.